Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. reports developments in clinical-stage oncology focused on azenosertib, an investigational WEE1 inhibitor being developed as a biomarker-driven treatment approach for ovarian cancer. Company updates commonly address Cyclin E1-positive platinum-resistant ovarian cancer, the DENALI, ASPENOVA and MUIR clinical programs, and scientific presentations involving ovarian cancer and triple-negative breast cancer research.
ZNTL news also includes financial results and operational updates, FDA-related clinical and regulatory disclosures, equity inducement grants under Nasdaq rules, and governance matters tied to the company’s public-company status.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced four poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, scheduled for April 25-30, 2025. The presentations focus on their WEE1 inhibitor, azenosertib, showcasing its potential in cancer treatment.
The posters will highlight:
- Cell-free DNA molecular response as a potential endpoint for measuring azenosertib's efficacy in high-grade serous ovarian cancer patients
- How loss of RB1 sensitizes TP53-mutated cancer cells to WEE1 inhibition by azenosertib
- Azenosertib's broad antitumor activity across various solid tumors
- Synergistic anti-tumor activity when combining azenosertib with encorafenib and cetuximab in BRAFV600E models
The presentations will take place between April 27-29, 2025, and the posters will be accessible through the Supporting Publications section on Zentalis's website.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has presented updated clinical data from Part 1b of the DENALI trial for azenosertib in platinum-resistant ovarian cancer (PROC) patients at the SGO 2025 Annual Meeting. The trial showed an objective response rate (ORR) of 34.9% in response-evaluable patients with Cyclin E1+ PROC tumors, and a median duration of response (mDOR) of 6.3 months.
The Phase 2 single-arm study evaluated azenosertib monotherapy at 400mg QD 5:2 dose in 102 PROC patients. The data demonstrated Cyclin E1 protein overexpression as a predictive biomarker, with approximately 50% of PROC patients overexpressing Cyclin E1. Common treatment-related adverse events included gastrointestinal toxicities and fatigue.
The company plans to initiate DENALI Part 2 in 1H 2025, with topline data expected by year-end 2026. If successful, the trial could support accelerated approval, subject to FDA review.
Zentalis Pharmaceuticals (ZNTL) has announced new equity grants under its 2022 Employment Inducement Incentive Award Plan. The company granted one newly hired employee 50,000 non-qualified stock options at an exercise price of $1.92 per share and 25,000 restricted stock units.
The stock options have a 10-year term with a four-year vesting schedule: 25% vesting after the first year and the remaining 75% vesting monthly over three years. The restricted stock units will vest in 25% increments annually over four years. Both grants are contingent on continued employment with Zentalis.
These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducement awards for individuals not previously employed by Zentalis, a clinical-stage biopharmaceutical company developing WEE1 inhibitor treatments for ovarian cancer and other tumor types.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has announced multiple presentations at the upcoming Society of Gynecologic Oncology (SGO) 2025 Annual Meeting, scheduled for March 14-17 in Seattle. The presentations include updated clinical data from the Phase 2 DENALI trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC).
Key highlights include an oral presentation by Dr. Fiona Simpkins focusing on Cyclin E1 as a predictive biomarker of azenosertib benefit in PROC patients, scheduled for March 15. Additionally, a poster presentation by Dr. Joanna Guo will showcase preclinical data demonstrating synergistic antitumor effects of azenosertib when combined with microtubule inhibitor-based antibody drug conjugates (ADCs).
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer and other tumor types, has announced its participation in two major investor conferences.
The company will participate in:
- The TD Cowen 45th Annual Health Care Conference in Boston, MA, with a fireside discussion scheduled for March 3, 2025, at 11:50 a.m. ET
- The Leerink Global Healthcare Conference in Miami, FL, with a fireside discussion scheduled for March 10, 2025, at 9:20 a.m. ET
Live webcasts and archived recordings of both events will be accessible through the 'Events & Presentations' tab on the Investors & Media section of Zentalis' website.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to one newly hired employee under its 2022 Employment Inducement Incentive Award Plan. The grant includes options to purchase 35,000 shares of common stock at an exercise price of $1.68 per share, matching the closing price on Nasdaq Global Market on the grant date.
The options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement for individuals not previously employed by Zentalis.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) has presented updated clinical data for azenosertib in treating Cyclin E1+ platinum-resistant ovarian cancer (PROC). The DENALI Part 1b study showed an Objective Response Rate (ORR) of approximately 35% in response-evaluable patients.
Key findings include a median duration of response of approximately 5.5 months, with patients continuing therapy. The safety profile remains well-characterized across over 350 patients treated at clinically active monotherapy doses, with no new safety concerns identified.
The company has aligned with FDA on the design of DENALI Part 2 study, expected to begin in 1H 2025, with topline data anticipated by year-end 2026. The study could potentially support accelerated approval, subject to FDA review. Notably, approximately 50% of PROC patients are Cyclin E1+, representing a substantial therapeutic and commercial opportunity.
Zentalis Pharmaceuticals (NASDAQ: ZNTL) announced a strategic restructuring to focus on late-stage development of its WEE1 inhibitor, azenosertib. The company plans a workforce reduction of approximately 40% to be completed in Q2 2025, extending its cash runway into late 2027.
The restructuring aims to support the execution of the potentially registration-enabling DENALI Part 2 study, with data readout anticipated by the end of 2026. The company will host a virtual corporate event on January 29, 2025, to present updated azenosertib clinical data and provide development and regulatory updates, including plans for registration-intent studies.
Zentalis Pharmaceuticals (ZNTL) announced that the FDA has granted Fast Track Designation to azenosertib for treating Cyclin E1-positive patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (PROC). This designation aims to expedite the development and review process for medicines addressing serious unmet medical needs.
The company published research in npj Precision Oncology demonstrating that high levels of Cyclin E1/CDK2 activation predict sensitivity to azenosertib. Zentalis will host a corporate webcast on January 29, 2025, to present comprehensive clinical data, including topline results from 102 patients in the Phase 2 DENALI study, final results from Phase 1b trial with 69 PROC patients, and data from 61 patients in the MAMMOTH trial. The event will also cover registration-intent study designs and regulatory updates.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its Compensation Committee has granted stock options to two newly hired employees on January 2, 2025. The grants include options to purchase 45,000 shares of common stock at an exercise price of $3.00 per share, matching the closing price on Nasdaq Global Market on the grant date.
The options were granted under the company's 2022 Employment Inducement Incentive Award Plan, following Nasdaq Listing Rule 5635(c)(4). These 10-year term options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following three years, contingent on continued employment.